Reductions in post‐hepatectomy liver failure and related mortality after implementation of the LiMAx algorithm in preoperative work‐up: a single‐centre analysis of 1170 hepatectomies of one or more segments  by Jara, Maximilian et al.
ORIGINAL ARTICLE
Reductions in post-hepatectomy liver failure and related mortality
after implementation of the LiMAx algorithm in preoperative
work-up: a single-centre analysis of 1170 hepatectomies of one or
more segments
Maximilian Jara, Tim Reese, Maciej Malinowski, Erika Valle, Daniel Seehofer, Gero Puhl, Peter Neuhaus,
Johann Pratschke & Martin Stockmann
Department for General, Visceral and Transplantation Surgery, Charite – Universit€atsmedizin Berlin, Berlin, Germany
Abstract
Objectives: Post-hepatectomy liver failure has a major impact on patient outcome. This study aims to
explore the impact of the integration of a novel patient-centred evaluation, the LiMAx algorithm, on
perioperative patient outcome after hepatectomy.
Methods: Trends in perioperative variables and morbidity and mortality rates in 1170 consecutive
patients undergoing elective hepatectomy between January 2006 and December 2011 were analysed
retrospectively. Propensity score matching was used to compare the effects on morbidity and mortality
of the integration of the LiMAx algorithm into clinical practice.
Results: Over the study period, the proportion of complex hepatectomies increased from 29.1% in
2006 to 37.7% in 2011 (P = 0.034). Similarly, the proportion of patients with liver cirrhosis selected for
hepatic surgery rose from 6.9% in 2006 to 11.3% in 2011 (P = 0.039). Despite these increases, rates
of post-hepatectomy liver failure fell from 24.7% in 2006 to 9.0% in 2011 (P < 0.001) and liver failure-
related postoperative mortality decreased from 4.0% in 2006 to 0.9% in 2011 (P = 0.014). Propensity
score matching was associated with reduced rates of post-hepatectomy liver failure [24.7% (n = 77)
versus 11.2% (n = 35); P < 0.001] and related mortality [3.8% (n = 12) versus 1.0% (n = 3); P = 0.035].
Conclusions: Postoperative liver failure and postoperative liver failure-related mortality decreased in
patients undergoing hepatectomy following the implementation of the LiMAx algorithm.
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Introduction
Improvements in rates of operative mortality after hepatic
tumour resection have broadened its use in the treatment of
patients with benign and malignant hepatobiliary disease.1,2
Extended resection has evolved as a suitable approach to ensure
complete tumour clearance in selected patients. Previous large
series have reported improved survival rates compared with
non-surgical strategies.3–8 As a result, radical approaches in
non-cirrhotic livers resulting in smaller remnant volumes have
become more commonplace.9 In patients with normal hepatic
function, remnant volume of 25% can be sufficient to avoid
postoperative hepatic failure.10 However, preoperative liver
function and intraoperative variables also have significant influ-
ence on patient outcomes and therefore must be considered.11
In patients with impaired hepatic function, there is no con-
sensus on what constitutes a safe residual liver volume follow-
ing hepatic resection.12,13 Several methods have been proposed
to assess remnant liver function.14–18 However, no preoperative
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approach has been widely accepted and pre-existing hepatic
dysfunction remains a major concern when considering
patients for hepatic resection. Selection criteria that accurately
identify patients in whom a surgical intervention can be safely
performed are required.
LiMAx (maximum liver function capacity) has recently been
proposed as a novel 13C-liver function breath test for the pre-
operative assessment of actual liver function before hepatec-
tomy and the prediction of patient outcome after surgery.19
LiMAx has been shown to be unaffected by age, gender or
obesity and has been demonstrated to accurately and reliably
assess liver function in both healthy subjects and patients with
cirrhosis.20–22 Based on these findings, the authors have pro-
posed a patient-centred preoperative evaluation for the risk
stratification (LiMAx algorithm) of patients prior to liver
surgery (Fig. 1).23
Figure 1 Clinical decision tree for preoperative evaluation of patients undergoing hepatectomy (modified according to Stockmann
et al.23). If pre-existing hepatic injury is unlikely and a small segmental resection (up to two segments) is planned, surgery can be
performed safely. However, in cases of suspected hepatic injury or planned larger resections, a preoperative LiMAx test to evaluate
actual enzymatic hepatic function is performed. In patients with normal liver function (LiMAx >315 lg/kg/h), resections of up to four
segments can be performed, but patients with considerably impaired liver function (LiMAx <140 lg/kg/h) should be refused and
alternative management options considered. In patients with intermediate liver function (LiMAx 140–315 lg/kg/h) or in whom major
hepatic resection (more than four segments) is planned, clinical decisions should be guided by preoperative volume/function analysis as
follows: resections with future remnant liver function (FRLF) of >100 lg/kg/h are feasible and safe; resections with FRLF of 80–100 lg/
kg/h represent critical interventions, and resections with an expected FRLF of <80 lg/kg/h should not be considered. In the last
category, alternative preoperative options such as portal vein embolization to increase future remnant liver volume,26 stenting in patients
with biliary obstruction and application of neoadjuvant chemotherapeutic regimes to reduce tumour volume and facilitate smaller
resections (colorectal liver metastases) should be considered.27 Hereafter, close LiMAx monitoring and preoperative repeated volume/
function analysis may help to ascertain the optimal timing for partial hepatic resection, even in patients with marginal LiMAx values
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Although the prognostic ability of LiMAx has already been
shown in prospective cohort studies, the aim of this study was
to investigate the effects on patient selection and outcome of
the introduction of the LiMAx algorithm.
Materials and methods
A retrospective analysis of all patients undergoing elective hepa-
tectomy at the Department for General, Visceral and Transplan-
tation Surgery, Charite – Universit€atsmedizin Berlin between 1
January 2006 and 31 December 2011 was performed. This period
was chosen because it centres around the introduction of the Li-
MAx algorithm in preoperative work-up in 2008 and 2009.
Exclusion criteria prevented the inclusion of patients undergoing
small wedge resections, additional major extrahepatic proce-
dures, emergency surgery and associated liver partition with
portal vein ligation for staged hepatectomy. The institutional
ethics committee waived requirements for informed consent
because the study was of a retrospective design.
Cases were retrieved from the hospital’s medical controlling
office. Perioperative and patient variables extracted from the
hospital’s information system were evaluated. Effects associated
with the integration of the LiMAx algorithm on the clinical
management and outcome of patients undergoing hepatectomy
were studied. Variables analysed included age, gender, Ameri-
can Society of Anesthesiologists (ASA) score, main diagnoses,
frequency of portal vein embolization and preoperative biliary
drainage, type of hepatic resection and postoperative variables
including Acute Physiology and Chronic Health Evaluation
(APACHE) II score after postoperative admission to the inten-
sive care unit (ICU), post-hepatectomy liver failure (PHLF),
number of postoperative days in the ICU, postoperative hospi-
tal length of stay (LoS) and mortality including cause. Post-
hepatectomy liver failure was defined according to the consen-
sus definition of the International Study Group of Liver Sur-
gery (ISGLS) based on international normalized ratio (INR)
and serum bilirubin on or after postoperative day 5.24
Patients were divided into four groups for the analysis of
perioperative variables according to whether they had under-
gone a segmental resection, left hepatectomy, right hepatec-
tomy or complex hepatectomy. Data for patients submitted to
segmental resection, left lobectomy and resections of other seg-
ments in different combinations were combined for analysis
within the ‘segmental resection’ group. Extended right hepatec-
tomies and resections with concomitant biliary and/or vascular
reconstruction were classified under ‘complex hepatectomies’.
The LiMAx algorithm for patient evaluation before hepatec-
tomy has been described previously.23 Lack of data precluded
the stratification of patients according to whether or not the
LiMAx algorithm had been used. However, LiMAx was not
used for clinical decision making in 2006 and 2007. The
LiMAx algorithm was introduced to clinical practice in 2008
and 2009, and by 2010 LiMAx and the LiMAx algorithm had
been fully integrated into the perioperative management of all
patients undergoing elective hepatectomy at the study centre.
Thus, to more clearly display any effects of the integration of
the LiMAx algorithm on patient outcome and in order to min-
imize confounding factors, patients submitted to surgery in
2006 and 2007 were matched with patients submitted to sur-
gery in 2010 and 2011 using propensity score matching. The
propensity score for each patient was estimated by applying a
logistic regression model based on eight variables: gender; age;
ASA score; diagnosis; presence of cirrhosis; type of hepatic
resection; performance of biliary or vascular resection, and
duration of surgery. Patients operated in either period were
matched with the counterpart from the opposite period with
the closest estimated propensity score.
Statistical analysis
Categorical data are presented as frequencies and percentages,
and numerical data are expressed as medians and interquartile
Table 1 Patient demographics and diagnoses in 1170 patients
submitted to elective hepatectomy of one or more segments
between January 2006 and December 2011
Variable Value
Male, n (%)
629 (53.8%)
Age, years, median (range)
63 (52–70)
ASA class, n (%)
I
39 (3.3%)
II
524 (44.8%)
III
515 (44.0%)
IV
92 (7.9%)
Cirrhosis, n (%)
127 (10.9%)
Diagnosis, n (%)
Malignant
999 (85.4%)
Colorectal liver metastases
343 (34.3%)
Hepatocellular carcinoma
185 (18.5%)
Hilar cholangiocarcinoma
173 (17.3%)
Others
298 (29.8%)
Benign
152 (13.0%)
Others
19 (1.6%)
ASA, American Society of Anesthesiologists.
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ranges unless otherwise stated. To account for missing values
(ASA score), multiple imputation for all participants to impute
10 values for each missing observation was performed and then
combined with multivariable modelling estimates. Trends over
time were analysed using the Cochran–Armitage test, which is
based on a linear probability model. In the matched cohort,
comparisons were performed using Wilcoxon signed rank tests
and McNemar tests with respect to data distribution. A P-value of
<0.05 was considered to indicate statistical significance. Statistical
analysis was performed using IBM SPSS Statistics for Windows
Version 21.0 (IBM Corp., Armonk, NY, USA) and R Version
3.0.3 (R Foundation for Statistical Computing, Vienna, Austria).
Table 2 Patient demographics and types of hepatic resection by year in 1170 patients submitted to elective hepatectomy of one or more
segments
2006 2007 2008 2009 2010 2011 P-value
Patients, n
175 194 198 204 187 212 <0.001
Age, years, median (IQR)
62 (53–68) 64 (53–70) 63 (53–70) 65 (54–71) 63 (52–69) 60 (50–71) 0.527
ASA class, n (%)
I
4 (2.3%) 3 (1.5%) 7 (3.5%) 11 (5.4%) 8 (4.3%) 6 (2.8%) 0.280
II
79 (45.1%) 82 (42.3%) 83 (41.9%) 96 (47.1%) 89 (47.6%) 95 (44.8%)
III
79 (45.1%) 89 (45.9%) 94 (47.5%) 83 (40.7%) 81 (43.3%) 89 (42.0%)
IV
13 (7.4%) 20 (10.3%) 14 (7.1%) 14 (6.9%) 9 (4.8%) 22 (10.4%)
Cirrhosis, n (%)
12 (6.9%) 16 (8.2%) 23 (11.6%) 26 (12.7%) 26 (13.9%) 24 (11.3%) 0.039
MELD score, median (IQR)
8 (7–11) 7 (6–8) 7 (7–9) 7 (7–8) 7 (6–7) 7 (6–8) 0.747
Portal vein embolization, n (%)
6 (3.4%) 16 (8.2%) 23 (11.6%) 17 (8.3%) 34 (18.2%) 24 (11.3%) <0.001
Preoperative drainage, n (%)
8 (4.6%) 18 (9.3%) 13 (6.6%) 13 (6.4%) 19 (10.2%) 17 (8.0%) 0.063
Type of resection, n (%)
Segmental resection
39 (22.3%) 29 (14.9%) 42 (21.2%) 65 (31.9%) 39 (20.9%) 51 (24.1%) 0.125
Left hepatectomy
31 (17.7%) 34 (17.5%) 31 (15.7%) 33 (16.2%) 19 (10.2%) 37 (17.5%) 0.347
Right hepatectomy
54 (30.9%) 61 (31.4%) 58 (29.3%) 39 (19.1%) 48 (25.7%) 44 (20.8%) 0.003
Complex hepatectomy
51 (29.1%) 70 (36.1%) 67 (33.8%) 67 (32.8%) 81 (43.3%) 80 (37.7%) 0.034
PHLF, n (%)
43 (24.6%) 45 (23.2%) 44 (22.2%) 42 (20.6%) 28 (15.0%) 19 (9.0%) <0.001
APACHE II score, median (IQR)
13 (10–17) 13 (10–16) 13 (10–17) 12 (9–15) 12 (8–15) 12 (9–17) 0.128
ICU stay, days, median (IQR)
2 (1–4) 1 (1–2) 1 (1–4) 1 (1–2) 1 (1–3) 1 (1–2) 0.138
Postoperative LoS, days, median (IQR)
14 (10–23) 14 (10–26) 14 (10–25) 13 (8–22) 15 (9–28) 12 (8–19) 0.083
Hospital death, n (%)
12 (6.9%) 11 (5.7%) 13 (6.6%) 11 (5.4%) 11 (5.9%) 10 (4.7%) 0.387
Liver failure-related death, n (%)
7 (4.0%) 6 (3.1%) 6 (3.0%) 4 (2.0%) 2 (1.1%) 2 (0.9%) 0.014
Trends over time were tested for significance using the Cochran-Armitage test.
P-values in bold are significant at P < 0.05.
APACHE II, Acute Physiology and Chronic Health Evaluation II; ASA, American Society of Anesthesiologists; ICU, intensive care unit; IQR, inter-
quartile range; LoS, length of stay; MELD, Model for End-stage Liver Disease; PHLF, post-hepatectomy liver failure.
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Table 3 Surgery-related characteristics of patients grouped by type of resection for the study period
Type of partial
resection
Variable 2006 2007 2008 2009 2010 2011 P-value
Segmental
resection
Patients, n
39 29 42 65 39 51 0.125
Cirrhosis, n (%)
5 (12.8%) 3 (10.3%) 7 (16.7%) 13 (20.0%) 11 (28.2%) 14 (27.5%) 0.015
Operating time, min,
median (IQR) 209 (158–235) 198 (163–249) 181 (152–218) 179 (141–227) 212 (166–260) 171 (135–215) 0.342
PHLF, n (%)
7 (17.9%) 1 (3.4%) 2 (4.8%) 4 (6.2%) 1 (2.6%) 1 (2.0%) 0.007
APACHE II score,
median (IQR) 14 (9–15) 10 (7–13) 12 (9–15) 13 (10–15) 11 (8–15) 11 (8–17) 0.699
ICU stay, days,
median (IQR) 1 (1–4) 1 (1–2) 1 (1–2) 1 (1–1) 1 (1–1) 1 (1–1) 0.926
Postoperative LoS,
days, median (IQR) 11 (8–15) 10 (8–19) 10 (8–13) 8 (7–13) 10 (7–15) 10 (7–15) 0.803
Hospital deaths, n (%)
4 (10.3%) 0 1 (2.4%) 2 (3.1%) 1 (2.6%) 1 (2.0%) 0.130
Liver failure-related
death, n (%) 2 (5.1%) 0 0 0 0 1 (2.0%) 0.272
Left
hepatectomy
Patients, n
31 34 31 33 19 37 0.347
Cirrhosis, n (%)
4 (12.9%) 5 (14.7%) 5 (16.1%) 4 (12.1%) 4 (21.1%) 3 (8.1%) 0.655
Operating time, min,
median (IQR) 235 (203–318) 232 (175–294) 249 (169–294) 137 (170–270) 235 (190–260) 191 (154–237) 0.007
PHLF, n (%)
3 (9.7%) 5 (14.7%) 3 (9.7%) 4 (12.1%) 0 1 (2.7%) 0.086
APACHE II score,
median (IQR) 12 (10–15) 13 (11–16) 13 (9–17) 10 (8–15) 11 (9–14) 11 (8–18) 0.312
ICU stay, days,
median (IQR) 1 (1–2) 1 (1–2) 1 (1–2) 1 (1–2) 1 (1–2) 1 (1–1) 0.073
Postoperative LoS,
days, median (IQR) 12 (8–17) 12 (10–19) 11 (9–18) 11 (10–20) 11 (7–14) 10 (7–13) 0.028
Hospital deaths, n (%)
1 (3.2%) 2 (5.9%) 0 2 (6.1%) 0 0 0.260
Liver failure-related
death, n (%) 0 1 (2.9%) 0 0 0 0 0.399
Right
hepatectomy
Patients, n
54 61 58 39 48 44 0.003
Cirrhosis, n (%)
2 (3.7%) 7 (11.5%) 7 (12.1%) 4 (10.3%) 5 (10.4%) 2 (4.5%) 0.975
Operating time, min,
median (IQR) 230 (199–261) 222 (189–259) 221 (175–287) 244 (193–283) 244 (100–293) 219 (171–269) 0.295
PHLF, n (%)
11 (20.4%) 14 (23.0%) 12 (20.7%) 8 (20.5%) 6 (12.5%) 4 (9.1%) 0.056
APACHE II score,
median (IQR) 15 (9–19) 14 (11–17) 13 (11–17) 12 (10–16) 12 (8–16) 14 (9–19) 0.338
ICU stay, days,
median (IQR) 1 (1–2) 1 (1–2) 1 (1–3) 1 (1–1) 1 (1–2) 1 (1–2) 0.556
Postoperative LoS,
days, median (IQR) 14 (10–20) 11 (9–19) 13 (9–22) 10 (8–15) 12 (9–20) 10 (8–14) 0.253
Hospital death, n (%)
2 (3.7%) 4 (6.6%) 3 (5.2%) 0 1 (2.1%) 3 (6.8%) 0.841
Liver failure-related
death, n (%) 1 (1.9%) 1 (1.6%) 2 (3.4%) 0 1 (2.1%) 0 0.487
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Results
Patient characteristics and extent of surgery
During the study period, 1302 adult patients underwent
hepatectomy. Following the application of the exclusion crite-
ria, 1170 consecutive patients submitted to elective hepatic
resection of one or more segments were found to be eligible
for analysis. Of the 68 patients who suffered in-hospital death,
48 (70.6%) met the criteria for PHLF and 20 (29.4%) did not.
Of the 48 patients with PHLF, 25 patients died as a result of
PHLF. One patient with PHLF underwent rescue liver trans-
plantation but died subsequently. Patient demographics and
data on the aetiologies of liver disease are shown in Table 1.
The proportion of patients undergoing laparoscopic resection
during the study period was 0.9% (n = 11).
Perioperative variables for individual years are summarized
in Table 2. The number of procedures (P < 0.001) and the
proportion of complex hepatectomies (P = 0.034) increased
significantly. The use of preoperative procedures such as portal
vein embolization to enhance future remnant liver volume and
liver function increased (P < 0.001). In addition, the propor-
tion of patients with liver cirrhosis undergoing surgery
increased (P = 0.039), whereas disease severity in those patients
as indicated by Model for End-stage Liver Disease (MELD)
scores remained stable (P = 0.747).
Further changes were analysed by stratifying patients into
four groups based on the extent of resection (Table 3). Over
the study period there was a progressive trend towards reduced
rates of PHLF in all groups. In particular, the proportion of
complex hepatectomies increased (P = 0.034), and rates of
PHLF and postoperative liver failure-related mortality declined
(P = 0.001 and P = 0.023, respectively). No significant trends
could be detected with respect to APACHE II score at
postoperative ICU admission, length of ICU stay or median
postoperative hospital LoS in any of the groups.
Effects in the matched patient cohort
Of the 369 patients who underwent hepatic resection in 2006
and 2007 and the 399 patients who underwent hepatic resection
during 2010 and 2011, 313 pairs were matched. After propensity
score matching, analysis yielded results similar to those observed
in all patients, with reduced rates of PHLF and reduced postop-
erative mortality caused by liver failure (Table 4).
Discussion
Over the 6-year study period, despite an increase in the
frequency at which complex hepatectomies were performed,
reductions in the rates of PHLF and postoperative liver fail-
ure-related mortality were observed. The analysis of data for
the propensity score-matched cohort suggests the integration
of the LiMAx algorithm may have been a major factor con-
tributing to the improved outcomes.
The preoperative identification of candidates in whom liver
surgery will be safe remains difficult, particularly in patients
with pre-existing hepatic dysfunction.25 As the present authors
have previously suggested, the accurate preoperative planning
of the intervention using LiMAx, a 13C-based test for the
determination of maximal liver function capacity, along with
Table 3 Continued
Type of partial
resection
Variable 2006 2007 2008 2009 2010 2011 P-value
Complex
hepatectomy
Patients, n
51 70 67 67 81 80 0.034
Cirrhosis, n (%)
1 (2.0%) 1 (1.4%) 4 (6.0%) 5 (7.5%) 6 (7.4%) 5 (6.3%) 0.177
Operating time, min,
median (IQR) 346 (255–407) 340 (283–381) 317 (266–390) 330 (272–366) 348 (282–450) 313 (228–385) 0.498
PHLF, n (%)
22 (43.1%) 25 (35.7%) 27 (40.3%) 26 (38.8%) 21 (25.9%) 13 (16.3%) <0.001
APACHE II score,
median (IQR) 13 (11–17) 13 (9–16) 15 (10–19) 13 (9–16) 12 (9–16) 12 (10–16) 0.359
ICU stay, days,
median (IQR) 4 (2–8) 1 (1–3) 3 (1–6) 1 (1–6) 1 (1–2) 1 (1–3) 0.170
Postoperative LoS,
days, median (IQR) 20 (14–32) 24 (15–41) 21 (14–35) 21 (14–50) 23 (16–41) 17 (11–27) 0.131
Hospital death, n (%) a
5 (9.8%) 5 (7.1%) 9 (13.6%)a 7 (10.4%) 9 (11.1%) 6 (7.5%) 0.896
Liver failure-related
death, n (%) 4 (7.8%) 4 (5.7%) 4 (6.0%)a 4 (6.0%) 1 (1.2%) 1 (1.3%) 0.023
a
One patient, who received a liver transplant, was excluded.
Trends over time were tested for significance using the Cochran–Armitage test.
P-values in bold are significant at P < 0.05.
APACHE II, Acute Physiology and Chronic Health Evaluation II; ICU, intensive care unit; IQR, interquartile range; LoS, length of stay; PHLF, post-
hepatectomy liver failure.
HPB 2015, 17, 651–658 ª 2015 International Hepato-Pancreato-Biliary Association
656 HPB
preoperative volume/function analysis, enables surgeons to cal-
culate future remnant liver function. The clinical decision tree
presented here might allow surgeons to offer individual and
safer treatment strategies.23
The current study shows that complex hepatectomies involv-
ing biliary or vascular reconstruction were performed increas-
ingly over the study period. Despite more complex procedures,
the decline in rates of PHLF and, in particular, the reduction
in the number of postoperative liver failure-related deaths in
the overall cohort demonstrate that the proposed system pro-
vides a valid estimation of individual operative risk. Similarly,
the increase in rates of portal vein embolization, the rise in the
proportion of patients with cirrhosis eligible for surgery and
the concomitant reduction in rates of PHLF further support
improved patient management and optimized preoperative
assessment.
In order to correct for the changes in surgical practice over
the years, a propensity score-matched analysis was performed
to more adequately estimate effects related to the full imple-
mentation of the LiMAx algorithm in clinical preoperative
work-up by the year 2010. This demonstrated a reduction in
postoperative liver failure-related death and PHLF, which sug-
gests that the LiMAx algorithm is of benefit to patients consid-
ered for surgery.
A major strength of this study is that the present analysis is
based on all consecutive and unselected patients submitted to
partial hepatic resection of one or more segments in an attempt
to overcome a potential selection bias. Charite Universit€atsmed-
izin Berlin represents one of 437 reference hospitals that contin-
uously report a distinct set of data (e.g. diagnoses, procedures,
case-related costs) to the German Institute for Remuneration in
Hospitals [Institut f€ur das Entgeltsystem im Krankenhaus
(InEK)] in order to facilitate a yearly calculation of revenues of
the German hospital system. Thus, the accuracy and validity of
the underlying medical controlling data are assured. A down-
side of the use of such data is that only a distinct set of parame-
ters routinely recorded by the controlling and strategy office in
the perioperative work-up were suitable for analysis and distinct
clinical parameters (e.g. operative blood loss, time of pedicle
clamping) could not be determined in this study.
Several limitations of this analysis should be mentioned.
Although the most significant improvements in operative tech-
nique were reported around the turn of the millennium, the
potential impacts of any effects based on general improvements
in surgical technique, anaesthetic care or intensive care nursing
cannot be excluded. However, hepatectomy was performed fol-
lowing a common surgical approach (Appendix S1, online) and
the vast majority of surgical procedures (70.8%) were per-
formed by three experienced liver surgeons. Thus it would seem
that any bias arising from the use of different surgical tech-
niques is unlikely. It is the authors’ opinion that the improved
outcomes are likely to be associated with the integration of the
LiMAx algorithm in routine work-up. Unfortunately, data on
the number of patients to whom surgery was denied based on
actual LiMAx data were not available. Hence, the current study
provides only a low level of evidence for the diagnostic accuracy
of LiMAx as a screening tool. Randomized controlled trials
would be beneficial to more clearly study the implications for
patient management of using a preoperative clinical decision
tree, such as that proposed, but these are difficult to perform.
In conclusion, the integration of the LiMAx algorithm seems
to have played an important role in optimizing risk assessment
prior to hepatic surgery.
Acknowledgements
The authors gratefully acknowledge the support of the staff of the Charite
Medical Controlling and Strategy Office in the provision of data. The authors
Table 4 Distribution of parameters within the cohorts of patients
submitted to elective hepatectomy of one or more segments
matched using propensity score matching
2006–2007 2010–2011 P-value
Patients, n
313 313
Age, years, mean  SEM
60  0.72 60  0.73 0.691
ASA class, n (%)
I
7 (2.2%) 8 (2.6%) 0.538
II
140 (44.7%) 139 (44.4%)
III
137 (43.8%) 146 (46.6%)
IV
29 (9.3%) 20 (6.4%)
Type of resection, n (%)
Segmental resection
53 (16.9%) 68 (21.7%) 0.790
Left hepatectomy
52 (16.6%) 46 (14.7%)
Right hepatectomy
97 (31.0%) 73 (23.3%)
Complex hepatectomy
111 (35.5% 126 (40.3%
PHLF, n (%)
77 (24.6%) 35 (11.2%) <0.001
ICU stay, days,
mean  SEM 5  0.73 3  0.56 0.001
Postoperative LoS,
days, mean  SEM 22  1.27 18  0.95 0.004
Hospital deaths, n (%)
19 (6.1%) 16 (5.1%) 0.735
Liver failure-related
death, n (%) 12 (3.8%) 3 (1.0%) 0.035
P-values in bold are significant at P < 0.05.
ASA, American Society of Anesthesiologists; ICU, intensive care unit;
LoS, length of stay; PHLF, post-hepatectomy liver failure; SEM, stan-
dard error of the mean.
HPB 2015, 17, 651–658 ª 2015 International Hepato-Pancreato-Biliary Association
HPB 657
would also like to thank the staff of the Institute for Biostatistics and Clinical
Epidemiology, Charite Universit€atsmedizin Berlin for assistance with statisti-
cal analyses.
Conflicts of interest
MS is the inventor of the LiMAx test and has a capital interest in Humedics
GmbH, Berlin, Germany, the company marketing the LiMAx test. MJ
received a research grant in the context of the d-LIVER European Commis-
sion Framework Programme.
References
1. Fan ST, Lo CM, Liu CL, Lam CM, Yuen WK, Yeung C et al. (1999) Hep-
atectomy for hepatocellular carcinoma: toward zero hospital deaths.
Ann Surg 229:322–330.
2. Belghiti J, Hiramatsu K, Benoist S, Massault P, Sauvanet A, Farges O.
(2000) Seven hundred forty-seven hepatectomies in the 1990s: an
update to evaluate the actual risk of liver resection. J Am Coll Surg
191:38–46.
3. Neuhaus P, Jonas S, Bechstein WO, Lohmann R, Radke C, Kling N
et al. (1999) Extended resections for hilar cholangiocarcinoma. Ann
Surg 230:808–818; discussion 819.
4. Clavien PA, Petrowsky H, DeOliveira ML, Graf R. (2007) Strategies for
safer liver surgery and partial liver transplantation. N Engl J Med
356:1545–1559.
5. Bismuth H, Adam R, Levi F, Farabos C, Waechter F, Castaing D et al. (1996)
Resection of nonresectable liver metastases from colorectal cancer after
neoadjuvant chemotherapy. Ann Surg 224:509–520; discussion 520–522.
6. Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW
et al. (2009) Improved survival in metastatic colorectal cancer is associ-
ated with adoption of hepatic resection and improved chemotherapy. J
Clin Oncol 27:3677–3683.
7. Feng K, Yan J, Li X, Xia F, Ma K, Wang S et al. (2012) A randomized
controlled trial of radiofrequency ablation and surgical resection in the
treatment of small hepatocellular carcinoma. J Hepatol 57:794–802.
8. Huang J, Yan L, Cheng Z, Wu H, Du L, Wang J et al. (2010) A random-
ized trial comparing radiofrequency ablation and surgical resection for
HCC conforming to the Milan criteria. Ann Surg 252:903–912.
9. Baer HU, Stain SC, Dennison AR, Eggers B, Blumgart LH. (1993)
Improvements in survival by aggressive resections of hilar cholangiocar-
cinoma. Ann Surg 217:20–27.
10. Shoup M, Gonen M, D’Angelica M, Jarnagin WR, DeMatteo RP, Sch-
wartz LH et al. (2003) Volumetric analysis predicts hepatic dysfunction
in patients undergoing major liver resection. J Gastrointest Surg 7:325–
330.
11. Jarnagin WR, Gonen M, Fong Y, DeMatteo RP, Ben-Porat L, Little S
et al. (2002) Improvement in perioperative outcome after hepatic resec-
tion: analysis of 1,803 consecutive cases over the past decade. Ann
Surg 236:397–406; discussion 406–407.
12. Parkin DM, Bray F, Ferlay J, Pisani P. (2005) Global cancer statistics,
2002. CA Cancer J Clin 55:74–108.
13. Robinson SM, Wilson CH, Burt AD, Manas DM, White SA. (2012) Che-
motherapy-associated liver injury in patients with colorectal liver metas-
tases: a systematic review and meta-analysis. Ann Surg Oncol
19:4287–4299.
14. Klein PD. (1982) Clinical applications of 13CO2 measurements. Fed Proc
41:2698–2701.
15. Armuzzi A, Candelli M, Zocco MA, Andreoli A, De Lorenzo A, Nista EC
et al. (2002) Review article: breath testing for human liver function
assessment. Aliment Pharmacol Ther 16:1977–1996.
16. Kubota K, Makuuchi M, Kusaka K, Kobayashi T, Miki K, Hasegawa K
et al. (1997) Measurement of liver volume and hepatic functional reserve
as a guide to decision-making in resectional surgery for hepatic tumors.
Hepatology 26:1176–1181.
17. Stremmel W, Wojdat R, Groteguth R, Zoedler M, Ebener T, Niederau C
et al. (1992) Liver function tests in a clinical comparison. Z Gastroenter-
ol 30:784–790.
18. Imamura H, Sano K, Sugawara Y, Kokudo N, Makuuchi M. (2005)
Assessment of hepatic reserve for indication of hepatic resection: deci-
sion tree incorporating indocyanine green test. J Hepatobiliary Pancreat
Surg 12:16–22.
19. Stockmann M, Lock JF, Riecke B, Heyne K, Martus P, Fricke M et al.
(2009) Prediction of postoperative outcome after hepatectomy with a
new bedside test for maximal liver function capacity. Ann Surg
250:119–125.
20. Lock JF, Malinowski M, Seehofer D, Hoppe S, Rohl RI, Niehues SM
et al. (2012) Function and volume recovery after partial hepatectomy:
influence of preoperative liver function, residual liver volume, and obes-
ity. Langenbecks Arch Surg 397:1297–1304.
21. Jara M, Bednarsch J, Valle E, Lock JF, Malinowski M, Schulz A et al.
(2015) Reliable assessment of liver function using LiMAx. J Surg Res
193:184–189.
22. Malinowski M, Jara M, Luttgert K, Orr J, Lock JF, Schott E et al. (2014)
Enzymatic liver function capacity correlates with disease severity of
patients with liver cirrhosis: a study with the LiMAx test. Dig Dis Sci
59:2983–2991.
23. Stockmann M, Lock JF, Malinowski M, Niehues SM, Seehofer D, Neu-
haus P. (2010) The LiMAx test: a new liver function test for predicting
postoperative outcome in liver surgery. HPB 12:139–146.
24. Rahbari NN, Garden OJ, Padbury R, Brooke-Smith M, Crawford M,
Adam R et al. (2011) Posthepatectomy liver failure: a definition and
grading by the International Study Group of Liver Surgery (ISGLS). Sur-
gery 149:713–724.
25. Wanless IR, Sweeney G, Dhillon AP, Guido M, Piga A, Galanello R et al.
(2002) Lack of progressive hepatic fibrosis during long-term therapy
with deferiprone in subjects with transfusion-dependent beta-thalasse-
mia. Blood 100:1566–1569.
26. Kumar M, Sakhuja P, Kumar A, Manglik N, Choudhury A, Hissar S et al.
(2008) Histological subclassification of cirrhosis based on histological–
haemodynamic correlation. Aliment Pharmacol Ther 27:771–779.
27. Nagula S, Jain D, Groszmann RJ, Garcia-Tsao G. (2006) Histological–
hemodynamic correlation in cirrhosis – a histological classification of
the severity of cirrhosis. J Hepatol 44:111–117.
Supporting information
Additional Supporting Information may be found in the online version of this
article:
Appendix S1. Standard operative and perioperative procedures.
HPB 2015, 17, 651–658 ª 2015 International Hepato-Pancreato-Biliary Association
658 HPB
